TWO Scottish companies are continuing the country’s world-renowned expertise in science with an initiative to speed up the development of vaccines, medicines and key ingredients for reducing antibiotic resistance.
Life sciences firm Cellexus, which is based in Dundee, has teamed up with electronics manufacturing services (EMS) company CB Technology in Livingston, who will produce a precision electronic controller unit for Cellexus’ CellMaker bioreactor.
Scientists can use the bioreactor to produce cells in their laboratories for use in experiments to develop new medicines and vaccines.
The CellMaker can also be used to make bacteriophages – types of viruses that infect bacteria – which can be used as an alternative to antibiotics in the farming industry.
Reducing the amount of antibiotics given to animals and fish will help tackle the growing problem of bacterial infections that have become resistant to antibiotics.
Cellexus’ CellMaker bioreactor has a small footprint in the laboratory, where space is often at a premium.
READ MORE: Resistance worries as study finds antibiotic use 'very high' in first Covid wave
Cells or bacteriophages will be grown inside single-use bags in the machine, which means researchers can swap between experiments quickly without having to clean the device, saving time and speeding up their work.
It also uses “airlift” technology, which bubbles gases up through the bags to stir the ingredients for creating cells, rather than using mechanical stirred bioreactors that then need to be cleaned with expensive chemicals.
Airlift allows researchers to produce higher quantities of cells or bacteriophages from each batch, improving their yield and efficiency.
John Cameron, managing director at CB Technology, said: “Scotland has a proud history of leading the world in science and technology and I’m excited that CB Technology has engaged with Cellexus and is continuing that tradition.
“Devices like the CellMaker bioreactor give scientists the key tools that they need to solve some of the biggest problems facing humanity, from developing new medicines and vaccines through to producing bacteriophages as alternatives to antibiotics in the food industry.
“Working with cutting-edge life sciences companies like Cellexus is an important and growing part of CB Technology’s business.”
Gavin Hands, chief executive at Cellexus, added: “We prefer to work with local companies whenever possible, and so having CB Technology within an hour’s drive of our laboratory made a huge difference while we were developing the manufacturing process of the CellMaker bioreactor.
“We were very impressed with their portfolio of work and their capabilities, especially their expertise in producing complex high reliability system assemblies, which was key in selecting them to build the controller for us.
“I was also very impressed with the way CB Technology managed the project launch, taking the lead through structured workshops and regular action tracker reviews to ensure they were ready to launch the first product builds.
“Our two companies were able to share the lessons we had learned from our processes and procedures with each other, which has ultimately made the CellMaker even better and has brought benefits for the scientists who will use it.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here